Showing 1 - 20 results of 32 for search 'Javier DE LA Rubia', query time: 0.08s Refine Results
  1. 1
    Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens"

    Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens" by Javier de la Rubia

    Published 2014-04-01
    Get full text
    Article
  2. 2
    Microangiopatía trombótica secundaria y eculizumab: una opción terapéutica razonable

    Microangiopatía trombótica secundaria y eculizumab: una opción terapéutica razonable by Elena Román, Santiago Mendizábal, Isidro Jarque, Javier de la Rubia, Amparo Sempere, Enrique Morales, Manuel Praga, Ana Ávila, José Luis Górriz

    Published 2017-09-01
    Get full text
    Article
  3. 3
    Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence

    Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence by Pilar Solves, Ana Bataller, Ana Belén Gálvez, Pedro Asensi Cantó, Marta Santiago, María José Moreno, Inés Gómez-Seguí, Javier de la Rubia

    Published 2024-03-01
    Get full text
    Article
  4. 4
    Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry

    Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry by Javier de la Rubia, Felipe de Arriba, Cristina Arbona, María J. Pascual, Concha Zamora, Andrés Insunza, Dorleta Martínez, Carmen Paniagua, Miguel A. Díaz, Miguel A. Sanz

    Published 2008-05-01
    Get full text
    Article
  5. 5
    Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies

    Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies by Federico Moscardó, Jaime Sanz, Leonor Senent, Susana Cantero, Javier de la Rubia, Pau Montesinos, Dolores Planelles, Ignacio Lorenzo, Jose Cervera, Javier Palau, Miguel A. Sanz, Guillermo F. Sanz

    Published 2009-06-01
    Get full text
    Article
  6. 6
    A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study

    A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study by Rafael Ríos-Tamayo, Juan Alfons Soler, Ricarda García-Sánchez, Ernesto Pérez Persona, Mario Arnao, Antoni García-Guiñón, Abel Domingo, Miriam González-Pardo, Javier de la Rubia, María Victoria Mateos

    Published 2023-12-01
    Get full text
    Article
  7. 7
    INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

    INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA by Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Filip Callewaert, Hilde De Winter

    Published 2021-11-01
    Get full text
    Article
  8. 8
    THE ROLE OF ADAMTS13 ACTIVITY LEVELS ON DISEASE EXACERBATION OR RELAPSE IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA: POST HOC ANALYSIS OF THE PHASE 3 HERCULES AND POST-HERCULES STUDIES

    THE ROLE OF ADAMTS13 ACTIVITY LEVELS ON DISEASE EXACERBATION OR RELAPSE IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA: POST HOC ANALYSIS OF THE PHASE 3 HERCU... by Johanna KREMER HOVINGA, Javier DE LA RUBIA, Katerina PAVENSKI, Ara METJIAN, Paul KNÖBL, Flora PEYVANDI, Spero CATALAND, Paul COPPO, Umer KHAN, Laurel A. MENAPACE, Ana PAULA MARQUES, Sriya GUNAWARDENA, Marie SCULLY

    Published 2023-10-01
    Get full text
    Article
  9. 9
    PB2477: INTEGRATION OF OPTICAL GENOME MAPPING IN DAILY CYTOGENETICS LABORATORY ROUTINE.

    PB2477: INTEGRATION OF OPTICAL GENOME MAPPING IN DAILY CYTOGENETICS LABORATORY ROUTINE. by Álvaro Díaz González, Gayane Avetisyan, Cristian Garcia-Ruiz, José Vicente Gil, Marta Santiago, Juan José Domínguez-García, Marta Llop, Eva Barragan, Maria Leonor Senent Peris, Javier DE LA Rubia, José Cervera, Esperanza Such

    Published 2023-08-01
    Get full text
    Article
  10. 10
    Genomic analysis of high-risk smoldering multiple myeloma

    Genomic analysis of high-risk smoldering multiple myeloma by Lucía López-Corral, María Victoria Mateos, Luis A. Corchete, María Eugenia Sarasquete, Javier de la Rubia, Felipe de Arriba, Juan-José Lahuerta, Ramón García-Sanz, Jesús F. San Miguel, Norma C. Gutiérrez

    Published 2012-09-01
    Get full text
    Article
  11. 11
    CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma

    CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma by Esperanza Such, José Cervera, Evangelos Terpos, José V Bagán, Amparo Avaria, Inés Gómez, María Margaix, Mariam Ibañez, Irene Luna, Lourdes Cordón, Mónica Roig, Miguel A. Sanz, Meletios A. Dimopoulos, Javier de la Rubia

    Published 2011-10-01
    Get full text
    Article
  12. 12
    Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

    Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model by Pau Montesinos, Ignacio Lorenzo, Guillermo Martín, Jaime Sanz, Maria Luz Pérez-Sirvent, David Martínez, Guillermo Ortí, Lorenzo Algarra, Jesus Martínez, Federico Moscardó, Javier de la Rubia, Isidro Jarque, Guillermo Sanz, Miguel A. Sanz

    Published 2008-01-01
    Get full text
    Article
  13. 13
    LONG-TERM OUTCOMES OF PATIENTS TREATED WITH CAPLACIZUMAB FOR IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP): THE POST-HERCULES STUDY

    LONG-TERM OUTCOMES OF PATIENTS TREATED WITH CAPLACIZUMAB FOR IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP): THE POST-HERCULES STUDY by Özgür Pektaş, Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knöbl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga, Jessica Minkue Mi Edou, Rui de Passos Sousa, Sriya Gunawardena, Julie Lin

    Published 2022-10-01
    Get full text
    Article
  14. 14
    UECOM Radio: Refuerzo de competencias mediante streaming y podcasting.

    UECOM Radio: Refuerzo de competencias mediante streaming y podcasting. by Juan José Ceballos Norte, Mohamed Lemrini El Ouahhabi, Rosa Mª Mateos Pizarro, Miguel Ángel Vázquez Fernández, José Barrero Muñoz, José Sánchez Sanz, Moisés Ruiz González, Javier de la Rubia Rubio, Luis Moser-Rothschild, Carlos Hierro Muñoz

    Published 2011-04-01
    Get full text
    Article
  15. 15
    UECOM Radio: Refuerzo de competencias mediante streaming y podcasting.

    UECOM Radio: Refuerzo de competencias mediante streaming y podcasting. by Juan José Ceballos Norte, Mohamed Lemrini El Ouahhabi, Rosa Mª Mateos Pizarro, Miguel Ángel Vázquez Fernández, José Barrero Muñoz, José Sánchez Sanz, Moisés Ruiz González, Javier de la Rubia Rubio, Luis Moser-Rothschild, Carlos Hierro Muñoz

    Published 2011-04-01
    Get full text
    Article
  16. 16
    Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study

    Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control s... by David Gallardo, Rafael de la Cámara, Jose B. Nieto, Ildefonso Espigado, Arturo Iriondo, Antonio Jiménez-Velasco, Carlos Vallejo, Carmen Martín, Dolores Caballero, Salut Brunet, David Serrano, Carlos Solano, Josep M. Ribera, Javier de la Rubia, Enric Carreras

    Published 2009-09-01
    Get full text
    Article
  17. 17
    P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY

    P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY by Javier DE LA Rubia, Inés Gómez-Seguí, Joan Cid, David Valcárcel, Rosa Goterris, Miguel Fernández Zarzoso, María Eva Mingot-Castellano, Cristina Pascual Izquierdo, Ana Oliva Hernández, Jorge Martínez Nieto, Laura F. Ávila Idrovo, María Liz Paciello Coronel, Luis M. Hernández

    Published 2023-08-01
    Get full text
    Article
  18. 18
    Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

    Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease by Laura Rosiñol, Ramón García-Sanz, Juan José Lahuerta, Miguel Hernández-García, Miquel Granell, Javier de la Rubia, Albert Oriol, Belén Hernández-Ruiz, Consuelo Rayón, Isabel Navarro, Juan Carlos García-Ruiz, Joan Besalduch, Santiago Gardella, Javier López Jiménez, Joaquín Díaz-Mediavilla, Adrián Alegre, Jesús San Miguel, Joan Bladé

    Published 2012-04-01
    Get full text
    Article
  19. 19
    Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

    Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial by Ramón García-Sanz, Albert Oriol, María J. Moreno, Javier de la Rubia, Angel R. Payer, Miguel T. Hernández, Luis Palomera, Ana I. Teruel, María J. Blanchard, Mercedes Gironella, Paz Ribas, Joan Bargay, Eugenia Abellá, Miquel Granell, Enrique M. Ocio, Josep M. Ribera, Jesús F. San Miguel, María V. Mateos

    Published 2015-09-01
    Get full text
    Article
  20. 20
    Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial

    Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial by María-Victoria Mateos, Albert Oriol, Laura Rosiñol, Felipe de Arriba, Noemí Puig, Jesús Martín, Joaquín Martínez-López, María Asunción Echeveste, Josep Sarrá, Enrique Ocio, Gemma Ramírez, Rafael Martínez, Luis Palomera, Angel Payer, Rebeca Iglesias, Javier de la Rubia, Adrian Alegre, Ana Isabel Chinea, Joan Bladé, Juan José Lahuerta, Jesús-F. San Miguel

    Published 2015-08-01
    Get full text
    Article

Search Tools: